RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous administration of a breast cancer therapy significantly decreased treatment time compared with IV ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

Immunotherapy, exemplified by Opdivo, enhances cancer treatment by targeting malignant cells using the immune system, offering a more precise approach than traditional therapies. The FDA approved ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

(Barcelona, Spain--September 9, 2025 at 11:30 AM CEST / UTC +2)— A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the ...

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...